Neuphoria Therapeutics (NEUP) Financial Statements & Analysis

Neuphoria Therapeutics (NEUP) Income Statement

Neuphoria Therapeutics reported revenue of AUD 1.17M in fiscal 2026 (fiscal year ended Jun 30, 2026), down 92.5% from AUD 15.65M a year earlier. Neuphoria Therapeutics posted a net loss of AUD 13.45M, compared with a net loss of AUD 369.63K a year earlier. Gross margin was 43.5% and operating margin -835.5%.

Neuphoria Therapeutics Income Statement Analysis

Values in billions AUD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Neuphoria Therapeutics Inc. income statement - Annual data in billions AUD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017
Revenue & Gross Profit
Revenue	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.03
Cost of Revenue	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.03	0.02
Gross Profit	0.00	0.02	0.00	0.00	-0.01	0.00	0.00	0.00	-0.01	0.00
Operating Expenses
Research & Development	3.55	0.01	0.01	0.01	-0.01	0.00	0.00	0.01	0.02	0.02
Selling, General & Administrative	7.44	0.01	0.01	0.01	0.01	0.00	0.00	0.01	0.00	0.01
Operating Expenses	0.01	0.02	0.02	0.02	-0.01	0.00	0.01	0.02	0.02	0.03
Operating Income	-0.01	0.00	-0.03	-0.02	0.01	0.00	-0.01	-0.01	-0.02	-0.01
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Income
Income Before Tax	-0.01	0.00	-0.02	-0.02	-0.02	-0.01	0.00	-0.01	-0.02	0.00
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-0.01	0.00	-0.02	-0.02	-0.02	-0.01	0.00	-0.01	-0.02	-0.01
Net Income - Continuous Operations	-0.01	0.00	-0.02	-0.02	-0.02	-0.01	0.00	-0.01	-0.02	-0.01
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	-0.01	0.00	-0.03	-0.02	-0.01	-0.01	0.00	-0.01	-0.02	0.00
EBIT	-0.01	0.00	-0.02	-0.02	-0.01	-0.01	-	-	-	-
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-3.00	-	-	-	-	-	-	-	-	-
Diluted EPS	-3.00	-	-	-43.00	-30.00	-16.00	-	-	-	-
Basic Shares Outstanding	0.00	0.00	0.15	1.47	1.35	0.78	0.05	0.04	0.04	0.04
Diluted Shares Outstanding	0.00	0.00	0.15	1.47	1.35	0.78	0.05	0.04	0.04	0.04

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Neuphoria Therapeutics Financial Statements

What was Neuphoria Therapeutics's revenue in fiscal 2026?

Neuphoria Therapeutics reported revenue of AUD 1.17M in fiscal 2026 (fiscal year ended Jun 30, 2026). That was down 92.5% from AUD 15.65M a year earlier.

Is Neuphoria Therapeutics profitable?

No. Neuphoria Therapeutics reported a net loss of AUD 13.45M in fiscal 2026. In fiscal 2025 it lost AUD 369.63K.

What is Neuphoria Therapeutics's operating margin?

Neuphoria Therapeutics's operating income was −AUD 9.81M on revenue of AUD 1.17M in fiscal 2026, an operating margin of -835.5%, compared with -7.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition